DOMPE

What DOMPE does

Dompé farmaceutici S.p.A. is a privately held Italian biopharmaceutical company founded in 1894 and headquartered in Milan, operating across approximately 40 countries with roughly 1,100 employees. The company is built around two proprietary technology pillars: recombinant human Nerve Growth Factor (rhNGF), for which Dompé spent seven years developing the first scalable manufacturing process, and the Exscalate AI-driven virtual screening platform for accelerated drug discovery. Its commercial portfolio spans prescription biotech products (most notably Oxervate/cenegermin-bkbj for neurotrophic keratitis, approved in the US and EU), a late-stage pipeline of NGF-based and ophthalmic candidates (cenegermin-bkbj Phase 3 for PCED, intranasal NGF Phase 2 for cerebral palsy and NAION, Isocyclosporin Phase 3 for AKC), and a broad OTC/consumer health portfolio (Oki, Okitask, Levotuss, Fluifort, Xamamina, Sequacor, Ferrofast, Bioritmon, Collirio Alfa, Euclorina) sold through Italian and European retail pharmacies.

Dompé operates a hybrid business model combining proprietary drug development with three monetizable revenue streams: (1) prescription biotech product sales distributed through specialty pharmacy and hub service partners, supported by the direct-to-patient Dompé CONNECT to Care (DC2C) program; (2) OTC and consumer health product sales through retail pharmacy chains; and (3) licensing and co-development revenue, evidenced by strategic partnerships with Takeda Pharmaceuticals and Engitix Ltd. The company also operates direct patient service programs such as SiCura for pulmonary hypertension patients in collaboration with ItaliAssistenza. Pricing for biotech products is not publicly disclosed; OTC products are sold at market-determined retail pricing. Reported 2025 sales were €1.704 billion, and a €1 billion R&D investment is planned across 2025–2028, signaling self-funded pipeline scaling rather than external capital reliance.

Dompé is family-controlled as a single-member Italian company (società a socio unico) with €50M share capital and a wholly-owned US subsidiary (Dompé U.S. Inc., Delaware, headquartered in San Mateo, CA). The company holds FDA and EU regulatory approvals for its lead product and is pursuing accelerated US pathways (including the FDA Commissioner's National Priority Voucher) for multiple pipeline indications. Manufacturing is anchored at the L'Aquila, Italy facility, with additional clinical and operational sites including Rome.

Name

DOMPE

Legal name

Dompé farmaceutici S.p.A.

Website

https://dompe.com

Company type

Private

Founded year

1894

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Dompé farmaceutici is a privately held Italian biopharmaceutical company developing recombinant human Nerve Growth Factor (rhNGF) therapies and an AI drug discovery platform (Exscalate), serving patients with rare ophthalmic and neurological diseases alongside a broad European OTC portfolio.

Ownership category

akta.pro rank

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Prescription Biopharmaceutical Products: Dompé generates revenue from proprietary biotech therapeutics including cenegermin-bkbj (marketed as Oxervate for neurotrophic keratitis in the US/EU) and pipeline candidates in ophthalmology and neurology. Revenue is derived from product sales to specialty pharmacies, hospitals, and healthcare providers.
2. Over-the-Counter (OTC) and Consumer Health Products: Dompé markets a broad portfolio of OTC and consumer health products including pain/inflammation (Oki, Okitask), cold and cough (Levotuss, Fluifort, Argotone), gastrointestinal (Xamamina Reflusso), cardiovascular (Sequacor, Frequil, Ferrofast), eye care (Collirio Alfa), dermatology (Euclorina), and supplements (Bioritmon, Cardioritmon Colesterolo). Sold through pharmacies and retail channels across Italy and Europe.
3. Licensing and Co-development Revenue: Dompé receives revenue through strategic partnerships and licensing agreements in drug discovery and development, as evidenced by collaborations with Takeda Pharmaceuticals and Engitix Ltd for ECM-targeted therapeutics discovery.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Dompé is a biopharmaceutical company that develops, manufactures, and commercializes proprietary therapeutics based on recombinant human Nerve Growth Factor (rhNGF), with a primary focus on rare ophthalmic and neurological conditions. The company markets a broad portfolio of over-the-counter medicines, dietary supplements, and consumer health products across Italy and Europe, while operating an AI-driven drug discovery platform (Exscalate) and an active clinical pipeline spanning ophthalmology, neurology, and pain indications.

Product overview

Dompé is a biopharmaceutical company operating in Italy and the U.S. with a portfolio spanning prescription drugs, OTC medications, and dietary supplements. The company is built on its proprietary Nerve Growth Factor (NGF) Platform and Exscalate virtual screening technology. Its product portfolio includes: (1) a pipeline of NGF-based drug candidates including cenegermin-bkbj for ophthalmic conditions (PCED, neurotrophic keratitis), intranasal NGF for cerebral palsy and NAION, and isocyclosporin for atopic keratoconjunctivitis; (2) Primary & Specialty Care OTC products including pain/inflammation treatments (Oki, Okitask, Artrosilene, Miotens), cold & cough remedies (Levotuss, Fluifort, Argotone), gastrointestinal products (Xamamina), cardiovascular medications (Frequil, Sequacor, Ferrofast), eye/skin/oral care (Collirio Alfa, Euclorina), and prevention supplements (Bioritmon, Cardioritmon). The company operates manufacturing facilities in Italy and the U.S. with approximately 1,100 employees globally.

Differentiator

Problem solved

Functional benefit

Brands

• Exscalate: Virtual screening platform developed by Dompé to accelerate the drug discovery and screening process
• Dompé CONNECT to Care (DC2C)
• Bioritmon
• Cardioritmon Colesterolo
• Collirio Alfa
• Euclorina
• Xamamina
• Xamamina Reflusso
• Levotuss
• Fluifort
• Argotone
• Prontinal
• Oki
• Okitask
• Oki gola
• Okidol
• Artrosilene
• Miotens
• Frequil
• Sequacor
• Ferrofast
• SiCura

Products and services

• Oxervate (cenegermin-bkbj) Recombinant human Nerve Growth Factor (rhNGF) ophthalmic solution approved and marketed for the treatment of neurotrophic keratitis (NK), a rare corneal disease. Sold through specialty pharmacy partners and the Dompé CONNECT to Care (DC2C) hub program to ophthalmologists and patients.
• Cenegermin-bkbj ophthalmic solution (PCED) Investigational recombinant human Nerve Growth Factor ophthalmic formulation being evaluated in Phase 3 (Orunea study) for the treatment of persistent corneal epithelial defect (PCED), targeting the underlying degenerative pathology of the cornea.
• Intranasal NGF (cenegermin-bkbj) for cerebral palsy Intranasal delivery formulation of recombinant human Nerve Growth Factor (cenegermin-bkbj) in Phase 2 development for the treatment of spastic cerebral palsy in pediatric patients, intended to address the underlying brain damage rather than only symptoms.
• Intranasal NGF for NAION Intranasal Nerve Growth Factor therapy for non-arteritic anterior ischemic optic neuropathy (NAION), a rare optic nerve condition with no currently approved treatments. Program selected for FDA Priority Voucher pilot.
• Isocyclosporin for AKC Investigational treatment for atopic keratoconjunctivitis (AKC), a chronic inflammatory eye disease, currently in Phase 3 clinical development.
• Remodulin (pulmonary arterial hypertension therapy) Pulmonary arterial hypertension (PAH) therapy offered by Dompé and supported by the SiCura home-care nursing and technical assistance program delivered with ItaliAssistenza.
• Frequil Antiarrhythmic medication containing flecainide, indicated for the treatment of atrial fibrillation and recommended by ESC 2024 guidelines.
• Sequacor Beta-blocker medication containing bisoprolol, indicated for the treatment of heart failure.
• Oki Over-the-counter pain and anti-inflammatory medication containing ketoprofen lysine salt, used for mild to moderate pain, headache, sore throat, and flu symptoms. Sold through retail pharmacies.
• Artrosilene Topical anti-inflammatory product for pain relief, distributed through Italian and European pharmacies.
• Miotens Muscle relaxant for treatment of back pain and muscle contractures, sold through Italian and European pharmacies.
• Levotuss Peripheral antitussive medication containing levodropropizine for symptomatic treatment of cough. Sold through retail pharmacies.
• Fluifort

Quantifiable outcome

• Phase 3 Orunea trial enrolling ~150 adult patients for cenegermin-bkbj in PCED, testing complete epithelial healing vs. placebo
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• American College of Eye Technicians (ACET)minorStrategic or Co-development Partner · 6 February 2026ACET partnered with pharmaceutical and medical device companies including Dompé, Alcon, Bausch + Lomb, EyePoint Pharmaceuticals, RxSight, and Topcon Healthcare for its 8-week virtual training program to address the growing shortage of ophthalmic technicians in the United States. Five cohorts are scheduled in 2026.
• Engitix LtdcoreStrategic or Co-development Partner · 8 January 2026Engitix Ltd, a London-based biotech developing extracellular matrix (ECM)-targeted therapeutics for cancer and fibrosis, holds strategic discovery and development agreements with Dompé Farmaceutici. Engitix raised a $25M Series A extension financing led by investor Michael Platt, with Dompé as an existing strategic partner.
• Takeda PharmaceuticalscoreStrategic or Co-development Partner · 8 January 2026Engitix holds discovery and development agreements with both Dompé Farmaceutici and Takeda Pharmaceuticals, positioning Dompé's Exscalate platform as a key enabler of multi-party drug discovery collaborations in cancer and fibrosis.
• ItaliAssistenzacoreChannel Partner/ Reseller/ DistributorDompé partners with ItaliAssistenza to deliver the SiCura program, a professional nursing and technical assistance service at home and remotely for physicians, patients, and caregivers of patients treated with Dompé's Remodulin pulmonary arterial hypertension therapy. The program improves patient quality of life and reduces unnecessary hospital visits.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/DompeFarma
• LinkedInlinkedin.com/company/dompe

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DOMPE